Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Hydrocortisone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 3/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 11/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 1.00 |
| ▸ | SERPINA6 | P08185 | 4/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 1.00 |
| ▸ | NR3C2 | P08235 | 4/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 3/20 | 1.00 |
| ▸ | PGR | P06401 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | SHBG | P04278 | 2/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 0.80 |
| ▸ | AR | P10275 | 2/20 | 0.78 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.78 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.73 |
| ▸ | TSHR | P16473 | 2/20 | 0.73 |
| ▸ | BLM | P54132 | 1/20 | 0.73 |
| ▸ | POLB | P06746 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrocortisone SCHEMBL6932400 | 1.00 | HIF1A (1.00) | HIF1AHSD17B10SERPINA6CYP3A4SMN1; SMN2 | |
| Hydrocortisone SCHEMBL6370134 | 1.00 | HIF1A (1.00) | HIF1AHSD17B10SERPINA6CYP3A4SMN1; SMN2 | |
| Hydrocortisone SCHEMBL1688689 | 1.00 | HIF1A (1.00) | HIF1AHSD17B10SERPINA6CYP3A4SMN1; SMN2 | |
| Hydrocortisone SCHEMBL13046615 | 1.00 | HIF1A (1.00) | HIF1AHSD17B10SERPINA6CYP3A4SMN1; SMN2 | |
| Hydrocortisone SCHEMBL15114813 | 1.00 | HIF1A (1.00) | HIF1AHSD17B10SERPINA6CYP3A4SMN1; SMN2 | |
| Hydrocortisone SCHEMBL24900238 | 1.00 | HIF1A (1.00) | HIF1AHSD17B10SERPINA6CYP3A4SMN1; SMN2 | |
| Hydrocortisone SCHEMBL13202859 | 1.00 | HIF1A (1.00) | HIF1AHSD17B10SERPINA6CYP3A4SMN1; SMN2 | |
| Hydrocortisone SCHEMBL5699764 | 1.00 | HIF1A (1.00) | HIF1AHSD17B10SERPINA6CYP3A4SMN1; SMN2 | |
| Hydrocortisone SCHEMBL10292969 | 1.00 | HIF1A (1.00) | HIF1AHSD17B10SERPINA6CYP3A4SMN1; SMN2 | |
| Hydrocortisone SCHEMBL19465688 | 1.00 | HIF1A (1.00) | HIF1AHSD17B10SERPINA6CYP3A4SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8524697-B2 | C20-C21 substituted glucocorticoid receptor agonists | MERCK SHARP & DOHME CORP. (US) | 2013-09-03 | — | — | US | disclosed |
| US-8524697-B2 | C20-C21 substituted glucocorticoid receptor agonists | MERCK SHARP & DOHME CORP. (US) | 2013-09-03 | — | — | US | disclosed |
| US-20120171126-A1 | NOVEL [3,2-c] HETEROARYL STEROIDS AS GLUCOCORTICOID RECEPTOR AGONISTS COMPOSITIONS AND USES THEREOF | PURAKKATTLE BIJU J (US) | 2012-07-05 | — | — | US | disclosed |
| US-20120171126-A1 | NOVEL [3,2-c] HETEROARYL STEROIDS AS GLUCOCORTICOID RECEPTOR AGONISTS COMPOSITIONS AND USES THEREOF | PURAKKATTLE BIJU J (US) | 2012-07-05 | — | — | US | disclosed |
| US-20110262368-A1 | C21 THIOETHERS AS GLUCOCORTICOID RECEPTOR AGONISTS | SCHERING CORPORATION (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110262368-A1 | C21 THIOETHERS AS GLUCOCORTICOID RECEPTOR AGONISTS | SCHERING CORPORATION (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110182828-A1 | C20-C21 SUBSTITUTED GLUCOCORTICOID RECEPTOR AGONISTS | SCHERING CORPORATION (US) | 2011-07-28 | — | — | US | disclosed |
| US-20110182828-A1 | C20-C21 SUBSTITUTED GLUCOCORTICOID RECEPTOR AGONISTS | SCHERING CORPORATION (US) | 2011-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110262368-A1 | C21 THIOETHERS AS GLUCOCORTICOID RECEPTOR AGONISTS | NR3C1, CYP4A11, NR3C2 | NR3C1 1/4885HIF1A 3131/4885HSD17B10 765/4885 |
| US-20120171126-A1 | NOVEL [3,2-c] HETEROARYL STEROIDS AS GLUCOCORTICOID RECEPTOR AGONISTS COMPOSITIONS AND USES THEREOF | NR3C1, NR3C2, MC2R | NR3C1 1/4885HIF1A 3190/4885HSD17B10 167/4885 |
| US-20110182828-A1 | C20-C21 SUBSTITUTED GLUCOCORTICOID RECEPTOR AGONISTS | NR3C1, MC2R, NR3C2 | NR3C1 1/4885HIF1A 3951/4885HSD17B10 799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.